Fresh analysis reveals that patients who come off new slimming jabs like Mounjaro or Wegovy tend to recover lost weight at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Findings released in a leading medical journal shows that while overweight people often shed about a fifth of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"People using such drugs need to be informed of the danger of quick weight regain when the treatment ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment weight within about one and a half years.
Analyzing Approaches
The research, which reviewed dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who shed pounds through dieting generally experience a less rapid creep back—perhaps 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts believe the way of the jabs accounts for the amplified rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the injections for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals argue that, considering the significant potential of relapse, the treatment is often life-long.
This view is reinforced by pharmaceutical companies, who say that the findings "underscore the persistent nature of obesity," comparing it to managing conditions like high blood pressure.
Patient Experiences
People who have stopped the medication describe a intense resurgence of cravings.
"I experienced a trigger activating and you're instantly ravenous," said an individual.
The struggle is compounded if users have not developed lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Recent estimates show that a significant number of adults in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is more common among females than males.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a magic solution and long-term success relies on combined behavioural management.
